dm+d

Unassigned

New Medicines

Relapsed/refractory mantle cell lymphoma (MCL) after a prior BTK inhibitor

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Highly selective, non-covalent Brutons tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signalling pathway
MCL is a high-grade form of non-Hodgkin lymphoma and accounts for about 3-10% of all cases of NHL [1].
Relapsed/refractory mantle cell lymphoma (MCL) after a prior BTK inhibitor
Oral

Chronic lymphocytic leukaemia (CLL) and small lymphocytic leukaemia (SLL) - second-line or greater

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Highly selective, non-covalent Brutons tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signalling pathway
CLL is the most common leukaemia in the Western world with an incidence of 4.2 per 100,000 per year [1]. MCL is a high-grade form of non-Hodgkin lymphoma and accounts for about 3-10% of all cases of NHL [2].
Chronic lymphocytic leukaemia (CLL) and small lymphocytic leukaemia (SLL) - second-line or greater
Oral